Core Insights - BioNTech SE (BNTX) is viewed positively due to the promising prospects of its anti-CTLA4 therapy, Gotistobart, for treating squamous non-small cell lung cancer (NSCLC) [1][2] - The therapy demonstrates a 54% reduction in death risk compared to standard chemotherapy and a survival rate of 63% versus 30% with chemotherapy [1] - The oncology pipeline of BioNTech is considered undervalued, with potential for combination therapies using in-house antibody-drug conjugates [2] Company Overview - BioNTech SE is a German biotechnology firm focused on developing and commercializing innovative immunotherapies and vaccines for cancer and infectious diseases [3] - The company gained recognition for creating the first approved mRNA-based drug, the Pfizer-BioNTech COVID-19 vaccine, branded as Comirnaty [3]